NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

"I just read the translated version of the German Product Label again. It reminded me that product viability is 36 months."

Your post brings up several questions. One would be whether the Germans addressed only the viability of prepared vaccine, or also any leftover tumor tissue.

Or maybe the policy is to always continue electrophoresis until all the vaccine possible is made from the available tumor tissue. But that seems doubtful. What about huge tumors?

Another question would be regarding the (low dose) comment. Many will remember all of your previous discussions about multiple low dosing. I only remember some of the discussions. I assume this dosing change was intended to avoid some kind of bottle-necks in the lymph passages / DC travel tubes or some such that I have heard you and Pyrr talk about. Or was the reason they tried low dosing just so they could dose more often, but it turned out that lower doses worked better due to the bottleneck issue, even when they did not dose more often...? ie, did they find this by accident? Which patient population did they vary these things for? The main trial patient population? Or did they learn these things elsewhere, and then petition to use what they learned in the main population?

This 36 month expiration in the German Product Label is what AVII believes pushed Pyrrho over the edge?